Moderna, Inc.(MRNA) - Stock detail

Moderna, Inc.

US
MRNA
Moderna, Inc.(Listing date: 12/07/2018)

Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.

AI Sentiment AnalystBuy
Sentiment Score8/10
Generated At:2026-06-03 17:40:48
Analysis is based on 20 news articles published between 2026-05-20 and 2026-06-03. Sources include reputable financial news outlets (The Wall Street Journal, Barron's, BioPharma Dive), investment analysis platforms (Motley Fool, Simply Wall St., Zacks), and market data providers (Barchart), with information aggregated via Yahoo Finance. The data is highly timely, with the most recent items published within 48 hours of the report generation.
News Overview

The news flow is overwhelmingly positive, justifying a positive re-rating with an expected short-term price impact of +3% to +8% and a near-term price target of $44-$48. The convergence of the CEPI partnership and the upcoming FDA advisory panel for the flu vaccine on June 18 creates a strong positive bias. Recommendation is to BUY on any minor pullbacks.

Positive
3
Neutral
1
Negative
0
Event Timeline
2026-05-20
Price Impact: +5% to +10%
medium-term
Moderna has secured a major partnership with CEPI for an Ebola vaccine, validating its platform beyond COVID-19 and providing non-dilutive R&D funding. Concurrently, the FDA has scheduled a crucial advisory panel meeting for its mRNA flu vaccine candidate on June 18, 2026, providing a clear near-term catalyst. A historical $2.25 billion patent settlement with Roivant Sciences also underscores the value of its IP.
2026-05-20
Price Impact: +3% to +7%
short-term
Analyst sentiment is strongly positive, with UBS significantly raising its price target. JPMorgan reinstated coverage on the large-cap biotech sector, describing it as at an 'inflection point,' improving general sentiment. Moderna is also highlighted as a top performer, 'trouncing' major peers like Lilly and Pfizer year-to-date in 2026, reinforcing positive momentum.
2026-05-20
Price Impact: 0% to +/- 2%
short-term
Moderna made a corporate governance change to its bylaws regarding lawsuit venues, which has minimal direct operational impact. A separate article discusses high-level regulatory and political headwinds ('MAHA chaos'), but concludes that biotech investors are tuning out this noise to focus on company fundamentals like Moderna's pipeline.
News Topics List

CEPI Partnership for Ebola Vaccine Development

2026-05-20positivePrice Impact: +5% to +10%medium-term
AI Key Summary
  • Moderna expanded its collaboration with CEPI to develop an mRNA vaccine for the Bundibugyo ebolavirus strain.
  • The partnership targets an ongoing outbreak in Central Africa and involves funding of up to $50 million.
  • This news validates Moderna's mRNA platform beyond COVID-19.
  • It directly addresses an urgent public health need.
  • It provides non-dilutive funding for R&D, strengthening the company's infectious disease ambitions.
Source

FDA Advisory Panel Date Set for Flu Vaccine Candidate

2026-05-20positivePrice Impact: +3% to +7%short-term
AI Key Summary
  • The FDA has scheduled an advisory committee meeting for June 18, 2026, to review Moderna's mRNA-based seasonal flu vaccine candidate (mRNA-1010).
  • This provides a clear, near-term catalyst for the stock within two weeks.
  • While the stock initially dropped 5.5% on the announcement, the setting of a definitive date reduces uncertainty.
  • It refocuses market attention on a major pipeline milestone.
Source

UBS Valuation Upgrade and Positive Analyst Sentiment

2026-05-20positivePrice Impact: 0% to +/- 2%short-term
AI Key Summary
  • UBS increased its price target on MRNA to $45 from $36 while maintaining a Neutral rating.
  • This represents a significant 25% increase in the target price.
  • The upgrade reflects improved analyst confidence in the company's value ahead of key pipeline catalysts.
  • JPMorgan reinstated coverage on large-cap biotech, describing the sector as at an 'inflection point,' improving general investment sentiment.
  • Moderna is highlighted as a biotech stock outperforming major peers like Lilly, Merck, and Pfizer in 2026 year-to-date.
Source

Patent Litigation Settlement and Corporate Governance

2026-05-20neutralPrice Impact: -long-term
AI Key Summary
  • News regarding Roivant Sciences' earnings highlighted a $2.25 billion global patent settlement with Moderna.
  • While the primary financial impact is historical, it underscores the value of Moderna's intellectual property.
  • The settlement removes a significant legal overhang, contributing to a cleaner investment story.
  • Moderna amended its bylaws to require Securities Act lawsuits be filed exclusively in federal district courts, a corporate governance action with minimal direct operational impact.
Source